Nov 11, 2021 / NTS GMT
Fredrik Thor - Redeye AB - Analyst
Okay. So the next company is Cyxone and CEO, Tara Heitner. Welcome, Tara, and take it away.
Tara Heitner - Cyxone AB - CEO
Thank you, pleasure to be here. Cyxone is a company based in Southern Sweden. And our focus is developing breakthrough therapies for disorders of the immune system, where our focus, our current focus, is on autoimmune diseases. Specifically, we're developing rabeximod for rheumatoid arthritis and T20K for multiple sclerosis.
And here you see our pipeline where I show we have two programs in Phase 2 clinical stage of development, as well as the program for multiple sclerosis, which is in the preclinical stage. Now, autoimmune diseases are characterized by the immune system, which normally is meant to protect one against diseases like infections and cancer. But instead, in the case of autoimmune disease, your immune system turns against you and attacks your own healthy tissues and organs.
In rheumatoid arthritis, your immune system attacks the tissues of your joint, the bone, and cartilage,
Cyxone AB at Redeye Life Science Day (Virtual) Transcript
Nov 11, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers